Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug Discovery: Overview01:26

Drug Discovery: Overview

Drug discovery is a multifaceted process involving extensive screening, testing, and optimization of lead compounds to identify potential new drugs for therapeutic use. It combines several approaches, including screening large numbers of natural products, chemical modification of known active molecules, identification of new drug targets, and rational design based on biological mechanisms and drug-receptor structure. These approaches are carried out in both academic research laboratories and...
Structure-Activity Relationships and Drug Design01:28

Structure-Activity Relationships and Drug Design

Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence its...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and β2-adrenergic receptors...
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
Principles of Drug Action01:24

Principles of Drug Action

Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Japanese society for cancer of the colon and rectum (JSCCR) guidelines 2024 for the clinical practice of hereditary colorectal cancer.

International journal of clinical oncology·2025
Same author

Clinical features and endoscopic polyp management of Peutz-Jeghers syndrome: the 2nd nationwide epidemiological survey in Japan.

Journal of gastroenterology·2025
Same author

Prevalence and Incidence of Peutz-Jeghers Syndrome and Juvenile Polyposis Syndrome in Japan: A Nationwide Epidemiological Survey in 2022.

Journal of gastroenterology and hepatology·2024
Same author

Nursing Records Regarding Decision-Making in Cancer Supportive Care: A Retrospective Study in Japan.

Healthcare informatics research·2024
Same author

Knowledge and Awareness of Cancer Genome Profiling Tests among Japanese Patients with Cancer.

Clinics and practice·2024
Same author

Extrapolating differential scanning calorimetry data for monoclonal antibodies to low temperatures.

Analytical biochemistry·2024
Same journal

Validation of AI-enabled surrogate models in quantitative systems pharmacology: a practical, context-of-use-driven review.

Drug discovery today·2026
Same journal

IdopNetworks: How to infer the individualized genetic architecture of genomics for precision medicine.

Drug discovery today·2026
Same journal

Organoid-AI platforms need integrated governance in drug discovery.

Drug discovery today·2026
Same journal

Inorganic nanoparticles for diagnostics, drug delivery and therapy for solid tumors.

Drug discovery today·2026
Same journal

HDAC11 as a potential therapeutic target for Alzheimer's disease.

Drug discovery today·2026
Same journal

From biologics to small-molecule modulators: The evolving landscape of interleukin-targeted therapeutics.

Drug discovery today·2026
See all related articles

Related Experiment Video

Updated: May 30, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

Finding a better path to drug selectivity.

Yuko Kawasaki1, Ernesto Freire

  • 1Department of Biology, Johns Hopkins University, Baltimore, MD 21218, USA.

Drug Discovery Today
|August 16, 2011
PubMed
Summary
This summary is machine-generated.

Achieving high drug selectivity is challenging, especially for protein families. This study reveals how chemical modifications, using polar or nonpolar groups, can enhance drug selectivity through distinct thermodynamic mechanisms.

More Related Videos

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Related Experiment Videos

Last Updated: May 30, 2026

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors
10:33

Development of Inhibitors of Protein-protein Interactions through REPLACE: Application to the Design and Development Non-ATP Competitive CDK Inhibitors

Published on: October 26, 2015

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English
14:34

A Bilingual Computational Workflow for Identifying Potential PLK1 Inhibitors in American Sign Language and English

Published on: April 3, 2026

Area of Science:

  • Medicinal Chemistry
  • Pharmacology
  • Biochemistry

Background:

  • Drug selectivity is crucial for therapeutic efficacy and minimizing side effects.
  • Achieving high selectivity against large families of related protein targets remains a significant challenge in drug discovery.
  • Two primary strategies exist for improving selectivity during lead optimization: enhancing target affinity or reducing off-target affinity.

Purpose of the Study:

  • To investigate the distinct mechanisms by which chemical modifications influence drug selectivity.
  • To correlate these mechanisms with the thermodynamic signatures of drug-target interactions.
  • To provide insights into optimizing drug selectivity for protein targets.

Main Methods:

  • Analysis of protease inhibitors with systematic variations in single functional groups.
  • Thermodynamic profiling of binding interactions.
  • Computational analysis of structure-activity relationships.

Main Results:

  • Nonpolar functional groups primarily enhance selectivity by increasing target affinity.
  • Polar functional groups predominantly improve selectivity by decreasing off-target affinity.
  • Distinct thermodynamic signatures characterize these two selectivity-enhancing mechanisms.

Conclusions:

  • Understanding the differential impact of polar and nonpolar groups is key to rational drug design.
  • Synergistic application of both selectivity-enhancing mechanisms can lead to maximal selectivity.
  • Thermodynamic analysis provides valuable insights for optimizing drug candidates against challenging targets.